LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 1 | E19 | 72 | hr | 2543 | 2891 | 5578 | 0.5182 | 0.1145 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 2 | E19 | 72 | hr | 2543 | 2695 | 5578 | 0.4831 | 0.0499 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 3 | E19 | 72 | hr | 2543 | 3094 | 5578 | 0.5546 | 0.1814 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 1 | D13 | 72 | hr | 2543 | 6021 | 5578 | 1.0793 | 1.1457 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 2 | D13 | 72 | hr | 2543 | 6321 | 5578 | 1.1331 | 1.2446 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 3 | D13 | 72 | hr | 2543 | 6171 | 5578 | 1.1062 | 1.1952 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 1 | M19 | 72 | hr | 2543 | 2568 | 5578 | 0.4603 | 0.0081 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 2 | M19 | 72 | hr | 2543 | 2585 | 5578 | 0.4634 | 0.0137 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 3 | M19 | 72 | hr | 2543 | 2840 | 5578 | 0.5091 | 0.0977 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 1 | H07 | 72 | hr | 2543 | 1866 | 5578 | 0.3345 | -0.2232 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 2 | H07 | 72 | hr | 2543 | 1819 | 5578 | 0.3261 | -0.2387 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 3 | H07 | 72 | hr | 2543 | 2010 | 5578 | 0.3603 | -0.1758 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 1 | C13 | 72 | hr | 2543 | 4457 | 5578 | 0.7989 | 0.6305 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 2 | C13 | 72 | hr | 2543 | 4342 | 5578 | 0.7783 | 0.5926 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 3 | C13 | 72 | hr | 2543 | 4341 | 5578 | 0.7781 | 0.5922 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 1 | D19 | 72 | hr | 2543 | 1575 | 5578 | 0.2823 | -0.3191 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 2 | D19 | 72 | hr | 2543 | 1890 | 5578 | 0.3388 | -0.2153 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 3 | D19 | 72 | hr | 2543 | 1733 | 5578 | 0.3107 | -0.2670 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 1 | N07 | 72 | hr | 2543 | 2145 | 5578 | 0.3845 | -0.1313 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 2 | N07 | 72 | hr | 2543 | 2275 | 5578 | 0.4078 | -0.0884 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 3 | N07 | 72 | hr | 2543 | 2253 | 5578 | 0.4039 | -0.0957 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 1 | O01 | 72 | hr | 2543 | 890 | 5578 | 0.1595 | -0.5448 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 2 | O01 | 72 | hr | 2543 | 578 | 5578 | 0.1036 | -0.6476 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 3 | O01 | 72 | hr | 2543 | 1045 | 5578 | 0.1873 | -0.4937 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 1 | O01 | 72 | hr | 2543 | 1017 | 5578 | 0.1823 | -0.5029 |